Search

Your search keyword '"Park, Chan Hyuk"' showing total 734 results
Start Over Author "Park, Chan Hyuk"
734 results on '"Park, Chan Hyuk"'

14. Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for Helicobacter pylori infection: Real‐world evidence.

Author

Jung, Byung Wook, Park, Chan Hyuk, and Jung, Yoon Suk

Subjects
*HELICOBACTER pylori, *HELICOBACTER pylori infections, *ABDOMINAL pain, *CONFIDENCE intervals, *CLARITHROMYCIN
Abstract

Background and Aim Methods Results Conclusions Tegoprazan, a novel potassium‐competitive acid blocker, has been approved for Helicobacter pylori eradication in Korea. We compared the efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for H. pylori eradication in real‐world clinical practice.We retrospectively analyzed data from patients with H. pylori infection treated with tegoprazan‐ or rabeprazole‐based concomitant therapies. The primary endpoint was H. pylori eradication rate. The secondary endpoint was adverse events.Among the 1474 included patients, 620 and 854 received tegoprazan‐ and rabeprazole‐based concomitant therapies, respectively. Intention‐to‐treat analysis showed no significant difference in the eradication rates between the tegoprazan‐ and rabeprazole‐based concomitant therapy groups (74.7% [95% confidence interval [CI], 71.1–78.0%] vs 72.7% [95% CI, 69.7–75.6%], P = 0.400). Per‐protocol analysis also demonstrated similar eradication rates for the groups (tegoprazan vs rabeprazole: 88.0% [95% CI, 85.0–90.6%] vs 85.9% [95% CI, 83.2–88.3%], P = 0.288). Although the overall adverse event rate did not differ between groups (tegoprazan vs rabeprazole, 39.2% vs 40.6%, P = 0.578), abdominal discomfort was less frequent in the tegoprazan group than in the rabeprazole group (1.3 vs 4.8%, P = 0.001).Tegoprazan‐ and rabeprazole‐based concomitant therapies for H. pylori eradication showed comparable efficacy and overall safety. The effect of tegoprazan on dose increases or other regimens, such as bismuth‐containing quadruple therapy, should be further evaluated, because the efficacy of tegoprazan‐based concomitant therapy may be suboptimal in regions where the clarithromycin resistance rate is high. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Ranitidine Use and Incident Cancer in a Multinational Cohort

Author

You, Seng Chan, primary, Seo, Seung In, additional, Falconer, Thomas, additional, Yanover, Chen, additional, Duarte-Salles, Talita, additional, Seager, Sarah, additional, Posada, Jose D., additional, Shah, Nigam H., additional, Nguyen, Phung-Anh, additional, Kim, Yeesuk, additional, Hsu, Jason C., additional, Van Zandt, Mui, additional, Hsu, Min-Huei, additional, Lee, Hang Lak, additional, Ko, Heejoo, additional, Shin, Woon Geon, additional, Pratt, Nicole, additional, Park, Rae Woong, additional, Reich, Christin G., additional, Suchard, Marc A., additional, Hripcsak, George, additional, Park, Chan Hyuk, additional, and Prieto-Alhambra, Daniel, additional

Published
2023
Full Text
View/download PDF

39. Ranitidine Use and Incident Cancer in a Multinational Cohort

Author

You, Seng Chan, Seo, Seung In, Falconer, Thomas, Yanover, Chen, Duarte-Salles, Talita, Seager, Sarah, Posada, Jose D., Shah, Nigam H., Nguyen, Phung Anh, Kim, Yeesuk, Hsu, Jason C., Van Zandt, Mui, Hsu, Min Huei, Lee, Hang Lak, Ko, Heejoo, Shin, Woon Geon, Pratt, Nicole, Park, Rae Woong, Reich, Christin G., Suchard, Marc A., Hripcsak, George, Park, Chan Hyuk, Prieto-Alhambra, Daniel, You, Seng Chan, Seo, Seung In, Falconer, Thomas, Yanover, Chen, Duarte-Salles, Talita, Seager, Sarah, Posada, Jose D., Shah, Nigam H., Nguyen, Phung Anh, Kim, Yeesuk, Hsu, Jason C., Van Zandt, Mui, Hsu, Min Huei, Lee, Hang Lak, Ko, Heejoo, Shin, Woon Geon, Pratt, Nicole, Park, Rae Woong, Reich, Christin G., Suchard, Marc A., Hripcsak, George, Park, Chan Hyuk, and Prieto-Alhambra, Daniel

Abstract

Importance: Ranitidine, the most widely used histamine-2 receptor antagonist (H2RA), was withdrawn because of N-nitrosodimethylamine impurity in 2020. Given the worldwide exposure to this drug, the potential risk of cancer development associated with the intake of known carcinogens is an important epidemiological concern. Objective: To examine the comparative risk of cancer associated with the use of ranitidine vs other H2RAs. Design, Setting, and Participants: This new-user active comparator international network cohort study was conducted using 3 health claims and 9 electronic health record databases from the US, the United Kingdom, Germany, Spain, France, South Korea, and Taiwan. Large-scale propensity score (PS) matching was used to minimize confounding of the observed covariates with negative control outcomes. Empirical calibration was performed to account for unobserved confounding. All databases were mapped to a common data model. Database-specific estimates were combined using random-effects meta-analysis. Participants included individuals aged at least 20 years with no history of cancer who used H2RAs for more than 30 days from January 1986 to December 2020, with a 1-year washout period. Data were analyzed from April to September 2021. Exposure: The main exposure was use of ranitidine vs other H2RAs (famotidine, lafutidine, nizatidine, and roxatidine). Main Outcomes and Measures: The primary outcome was incidence of any cancer, except nonmelanoma skin cancer. Secondary outcomes included all cancer except thyroid cancer, 16 cancer subtypes, and all-cause mortality. Results: Among 1 183 999 individuals in 11 databases, 909 168 individuals (mean age, 56.1 years; 507 316 [55.8%] women) were identified as new users of ranitidine, and 274 831 individuals (mean age, 58.0 years; 145 935 [53.1%] women) were identified as new users of other H2RAs.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results